Page 2 - மறுக்க போவல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மறுக்க போவல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மறுக்க போவல் Today - Breaking & Trending Today

Don't forget caregivers during June Alzheimer's, Brain Awareness month

Don't forget caregivers during June Alzheimer's, Brain Awareness month
patriotledger.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from patriotledger.com Daily Mail and Mail on Sunday newspapers.

South Shore , United States , Denise Powell , Brain Awareness , Account Manager , Caregiver Homes , Patriot Ledger , தெற்கு கரை , ஒன்றுபட்டது மாநிலங்களில் , மறுக்க போவல் , மூளை விழிப்புணர்வு , எண்ணுதல் மேலாளர் , பராமரிப்பாளர் வீடுகள் , தேசபக்தர் பேரேடு ,

Novome Biotechnologies Appoints Dr. David N. Cook and Zachary Hornby to its Board of Directors

Novome Biotechnologies Appoints Dr. David N. Cook and Zachary Hornby to its Board of Directors
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Stanford University , United States , Neurocrine Biosciences , Blake Wise , Zachary Hornby , Denise Powell , Dan Janney , Andrew Schwab , Davidn Cook , Novome Biotechnologies Inc , University Of California , Harvard Business School , Company Board Of Directors , Harvard University , Vaccine Initiative , Novome Biotechnologies , Novome Board , Chief Executive Officer , Managing Partner , Kiersten Stead , Alta Partners , Will Deloache , Chief Scientific Officer , Senior Vice President , Forma Therapeutics , Seres Therapeutics ,

Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting

- Toripalimab data will also be featured in ASCO's official press program -SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences" ....

United States , Patricia Keegan , Junshi Bioscience , Eli Lilly , Mcdavid Stilwell , Denise Powell , Junshi Biosciences , Coherus Biosciences , Exchange Commission On , Coherus Biosciences Inc , Shanghai Junshi Biosciences Co Ltd , Committee On Foreign Investment , Pr Team , Abbvie Inc , Institute Of Microbiology Chinese Academy Science , Ir Team , Drug Administration , Genentech Inc , Exchange Commission , National Reimbursement Drug List , National Medical Products Administration , Chief Medical Officer , National Reimbursement Drug , Biologics License Application , Breakthrough Therapy Designation , Fast Track ,

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting

June 3, 2021, 5:00 p.m. Eastern Daylight Time
“We are excited that results of JUPITER-02, a Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, have been selected for presentation during ASCO’s plenary session, which traditionally features high-impact studies,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “Treatment of nasopharyngeal carcinoma, a specific type of head-and-neck cancer, is challenging, as the diagnosis usually occurs when the cancer is in an advanced stage and treatment options are limited.”
In addition to the JUPITER-02 late-breaking abstract, ASCO accepted for publication or presentation more than two dozen additional abstracts, primarily investigator-sponsored studies, that evaluate the utility of toripalimab in a variety of cancer types including lung cancer, melanoma, urothelial carcinoma, gastroesophageal cancer and hepatobi ....

United States , San Francisco , Patricia Keegan , Junshi Bioscience , Eli Lilly , Mcdavid Stilwell , Denise Powell , Junshi Biosciences , Coherus Biosciences , Institute Of Microbiology Chinese Academy Science , Ir Team , Coherus Biosciences Inc , Drug Administration , Genentech Inc , Shanghai Junshi Biosciences Co Ltd , Exchange Commission , Committee On Foreign Investment , National Reimbursement Drug List , National Medical Products Administration , Abbvie Inc , Pr Team , Plenary Session , Chief Medical Officer , National Reimbursement Drug , Biologics License Application , Breakthrough Therapy Designation ,

Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma

Bookmark of this page has been deleted.
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma
REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) Coherus BioSciences, Inc. ( CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, an anti-PD-1 monoclonal antibody, in combination with paclitaxel/cisplatin as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC), has achieved the pre-specified primary endpoints of progression free survival (PFS) and overall survival (OS) at the interim analysis. JUPITER-06 is a randomized, double-blind, placebo-controlled, multi-center, phase 3 clinical trial initiated in 2019 with 514 patients enrolled. ....

United States , Ruihua Xu , Denise Powell , Mcdavid Stilwell , Junshi Bioscience , Coherus Biosciences , Junshi Biosciences , Exchange Commission On , Coherus Biosciences Inc , Drug Administration , Genentech Inc , Data Monitoring Committee , Sun Yat Sen University Cancer Hospital , Exchange Commission , Committee On Foreign Investment , Abbvie Inc , Independent Data Monitoring Committee , Biologics License Application , Breakthrough Therapy Designation , Fast Track , Esophageal Squamous Cell Carcinoma , Blinded Independent Review Committee , Private Securities Litigation Reform Act , Hart Scott Rodino Antitrust Improvements Act , Foreign Investment , Coheru Annual Report ,